Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2.
about
Mechanisms of bone anabolism regulated by statinsActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsLipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle.Use of cell-based screening to identify small-molecule compounds that modulate claudin-4 expression.Statins Increase Plasminogen Activator Inhibitor Type 1 Gene Transcription through a Pregnane X Receptor Regulated Element.Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.Lovastatin-Mediated Changes in Human Tendon CellsLovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects modelA review of statin use and prostate cancer.Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry.Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress.Pleiotropic Effects of Statins on the Cardiovascular System.Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse modelsInsights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy.
P2860
Q26992028-46BF3A0B-F119-41BC-A743-1A2B6B653460Q27027458-43956081-FA79-4AAB-9BF2-CB4DF19E489BQ34221540-6F99954D-722F-49BD-84F8-EC9A2BDA7102Q35564741-C7494797-6DE6-4EC1-958B-3BF19B5D3AE7Q35778684-D058F901-6971-4928-8EAE-C8AF0A454DA3Q35897294-D5F17D7C-6E36-4C1A-BCCF-4F3B2023CD14Q36799885-A57A0F56-AAE3-4E8E-979B-F3D88884B9B4Q37402139-2F58A1DC-D509-4D30-82A0-F532CF226AD2Q38272644-2EE6388C-1D61-4D91-A0BC-D981F8A700CDQ38423044-94F41856-A780-4F62-8E51-A714E4B4740CQ38597093-65F20E98-DEA0-4E2B-B7BC-BF8859826EA3Q38649864-2B71A9C5-575E-4BBD-8CAF-80138C5D532BQ39069187-9D76D729-C8EE-4DCF-97F8-8CF9A1D9BE24Q42132309-BDF89DA9-B54C-4566-AE4C-C59F450BD9EBQ49300240-9585E79F-2E6C-453A-9F99-DE36701C94A3
P2860
Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@ast
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@en
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@nl
type
label
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@ast
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@en
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@nl
prefLabel
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@ast
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@en
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@nl
P2093
P2860
P356
P1476
Therapeutic levels of the hydr ...... ignaling via phospholipase D2.
@en
P2093
Guangwei Du
John F Hancock
Kwang-Jin Cho
Sravanthi Chigurupati
P2860
P304
P356
10.1128/MCB.00989-10
P407
P577
2011-01-18T00:00:00Z